Table 2. Immunohistochemical analysis of patients with endometrial cancer.
| Total | Rb | Phospho-Rb | P16 | Cyclin D1 | |||||
|---|---|---|---|---|---|---|---|---|---|
| positive | negative | positive | negative | positive | negative | positive | negative | ||
| Number of patients | 337 | 228 (67.7) | 109 (32.3) | 110 (32.6) | 227 (67.4) | 283 (84.0) | 54 (16.0) | 177 (52.5) | 160 (47.5) |
| Grade | |||||||||
| Low | 241 (71.5) | 159 (69.7) | 82 (75.2) | 72 (65.5) | 169 (74.5) | 202 (71.4) | 39 (72.2) | 117 (66.1)* | 124 (77.5)* |
| High | 96 (28.5) | 69 (30.3) | 27 (24.8) | 38 (34.6) | 58 (25.6) | 81 (28.6) | 15 (27.8) | 60 (33.9)* | 36 (22.5)* |
| Invasion | |||||||||
| No deep invasion | 190 (56.4) | 119 (52.2)* | 71 (65.1)* | 79 (71.8)* | 111 (48.9)* | 154 (54.4) | 36 (66.7) | 100 (56.5) | 90 (56.3) |
| Deep invasion | 147 (43.6) | 109 (47.8)* | 38 (34.9)* | 31 (28.2)* | 116 (51.1)* | 129 (45.6) | 18 (33.3) | 77 (43.5) | 70 (43.8) |
*Significant difference between the groups (p<0.05); Low grade, endometrioid carcinoma G1 or G2; High grade, endometrioid carcinoma G3, carcinosarcoma, serous carcinoma and clear cell carcinoma; No deep invasion, < 50% myometrial invasion without metastasis; Deep invasion, ≥50% myometrial invasion